+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dravet Syndrome Market by Drug Class, End User, Distribution Channel, Route of Administration, Patient Age Group - Global Forecast to 2030- Product Image
Dravet Syndrome Market by Drug Class, End User, Distribution Channel, Route of Administration, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Dravet Syndrome Market by Drug Class, End User, Distribution Channel, Route of Administration, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6084060
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dravet Syndrome Market grew from USD 734.04 million in 2024 to USD 800.08 million in 2025. It is expected to continue growing at a CAGR of 8.75%, reaching USD 1.21 billion by 2030.

Defining the Urgency in Dravet Syndrome Pathways

Dravet Syndrome presents some of the most formidable challenges in neurology, characterized by its onset in infancy, relentless seizure activity, and profound developmental delays. As we navigate the complexities of this rare channelopathy, it becomes clear that conventional therapeutic approaches often fall short of delivering sustained relief. The relentless nature of fever-induced and refractory seizures demands a multidisciplinary strategy that bridges cutting-edge science with compassionate care. With increasing recognition of the syndrome’s genetic underpinnings, there is a critical opportunity to translate molecular discoveries into targeted interventions.

This executive summary synthesizes the latest developments in treatment modalities, market dynamics, and patient-centered innovations. By examining regulatory milestones, shifts in reimbursement frameworks, and emerging modalities, we aim to provide stakeholders with a panoramic view of the opportunities and obstacles that define today’s landscape. Our goal is to equip clinicians, payers, and industry leaders with a cohesive narrative that supports evidence-based decision-making and fuels the next generation of therapeutic breakthroughs.

Emerging Paradigms Reshaping Treatment Horizons

The therapeutic horizon for Dravet Syndrome is undergoing profound metamorphosis as novel modalities emerge from the confluence of genetic research, real-world evidence platforms, and patient advocacy. Cannabinoid formulations have transcended early skepticism, earning approval for refractory seizure management and spurring investments in precision dosing. Meanwhile, renewed interest in sodium channel blockade has invigorated the pipeline, with next-generation topiramate analogues designed to enhance central nervous system selectivity and reduce systemic side effects.

In parallel, the adoption of telemedicine has streamlined multidisciplinary care delivery, enabling remote EEG monitoring and virtual consultations that improve adherence and seizure tracking. Advances in gene therapy have catalyzed proof-of-concept studies, with antisense oligonucleotides targeting SCN1A mutations offering a potential disease-modifying approach. These shifts are underpinned by enhanced collaborative networks that unite patient registries, academic consortia, and health technology assessors. As value-based care paradigms become the norm, payers are now evaluating total cost of care rather than isolated drug prices, thereby incentivizing durable clinical outcomes and integrated support services.

Assessing the Ripple Effects of U.S. Tariffs on 2025 Therapies

The implementation of new tariff structures in 2025 has exerted a measurable influence on manufacturing and distribution costs of orphan drugs, including those indicated for Dravet Syndrome. Higher duties on imported active pharmaceutical ingredients have necessitated reassessment of sourcing strategies, prompting some manufacturers to localize production in free-trade jurisdictions to mitigate incremental expenses. This realignment, while preserving supply chain continuity, has introduced transitional costs that are often reflected in list prices and reimbursement negotiations.

Health systems, especially those reliant on imported specialty pharmaceuticals, are experiencing budgetary pressures that require budget reallocation across therapeutic areas. Payers have responded by strengthening utilization management protocols and exploring biosimilar or generics pathways where feasible. Simultaneously, patient support programs have expanded to bridge cost barriers, leveraging copay assistance and foundation grants. The combined effect of tariffs and adaptive industry responses underscores the need for ongoing dialogue between regulators, manufacturers, and providers to ensure that access to critical Dravet Syndrome therapies remains uninterrupted and economically sustainable.

Unveiling Depths of Market Segmentation Dynamics

Market segmentation unveils nuanced dynamics that inform tailored commercial and clinical strategies. Within drug classes, cannabinoids have bifurcated into cannabidiol and tetrahydrocannabinol formulations, each demonstrating distinct efficacy and safety profiles. GABA modulators encompass clobazam, diazepam, and stiripentol, highlighting a spectrum of therapeutic intensities that address breakthrough seizures. Sodium channel blockers such as topiramate and valproate continue to serve as foundational therapies, though evolving formulations aim to optimize pharmacokinetics and tolerability.

The end-user landscape features home care settings that prioritize caregiver education and remote monitoring, hospitals equipped with specialized epilepsy units, and dedicated epilepsy centers that deliver comprehensive diagnostic and therapeutic services. Distribution pathways extend from hospital pharmacies and brick-and-mortar retail outlets to burgeoning online and specialty pharmacies, reflecting patient preferences for convenience and continuity. Routes of administration cover invasive injectables, noninvasive nasal sprays, oral tablets and liquids, oromucosal preparations, and transdermal systems, each unlocking new opportunities for personalization.

Demographically, treatment approaches must account for unique requirements across infants, children, adolescents, and adults. Developmental pharmacology principles, dosage adjustments, and safety monitoring protocols differ substantially by age, underscoring the importance of segmentation-driven clinical development and market deployment strategies.

Decoding Regional Variances in Disease Management

Regional landscapes for Dravet Syndrome vary in regulatory pathways, reimbursement structures, and healthcare infrastructure maturity. In the Americas, robust rare disease legislation and expanded compassionate use programs have facilitated early access to cannabinoid and gene-targeted therapies. The intricate network of private and public payers in this region demands flexible pricing models that balance innovation incentives with budget impact constraints.

Europe, Middle East & Africa present a mosaic of adoption curves, where centralized EMA approvals coexist with country-specific health technology assessments that influence market access timelines. Nations with established rare disease frameworks are pioneering risk-sharing agreements, while emerging markets grapple with supply chain limitations and affordability challenges. In the Asia-Pacific, fast-growing patient registries and clinical trial sites are accelerating data generation, yet disparities in per-capita healthcare spending necessitate tiered launch strategies to ensure equitable distribution.

Profiling Pioneers Driving Therapeutic Advancements

A cohort of specialized biopharma companies is spearheading therapeutic progress in Dravet Syndrome. Leaders in cannabinoid innovation have capitalized on extensive clinical trial portfolios to secure broad labels, while gene therapy pioneers are advancing beyond preclinical milestones with first-in-class candidates. Established epilepsy drug manufacturers are reinvesting in next-generation formulations that claim enhanced safety, and select orphan drug specialists are forging alliances to co-develop adjuvant therapies that target underlying pathophysiology.

Mergers and acquisitions have intensified as strategic buyers seek to expand portfolios with high-value orphan assets. Collaborative ventures between academic spin-outs and global pharma giants have yielded streamlined development pathways, marrying nimble research capabilities with commercial scale. Meanwhile, technology firms offering digital seizure monitoring and adherence platforms have emerged as critical partners, enabling real-time data collection that informs both clinical trials and post-market evidence generation.

Strategic Roadmap for Leaders Navigating Growth Trajectories

Industry leaders should prioritize diversification of supply chains by establishing regional manufacturing hubs and forging partnerships that reduce reliance on singular import routes. Investment in digital health solutions, including remote EEG monitoring and AI-enabled seizure prediction, will enhance patient engagement and generate actionable real-world data. Further, adopting value-based contracting frameworks tied to long-term clinical outcomes can align incentives across stakeholders and mitigate budget impact concerns.

Stakeholders are encouraged to accelerate early-stage research into gene modulation therapies, leveraging emerging antisense oligonucleotide platforms that directly address SCN1A mutations. Equally important is the expansion of patient advocacy collaborations to refine trial designs and ensure that endpoints resonate with quality-of-life improvements. Lastly, a proactive dialogue with regulatory bodies can facilitate adaptive licensing pathways and conditional reimbursement models, expediting access for life-threatening conditions.

Rigorous Framework Underpinning Our Research Approach

This report synthesizes insights derived from an integrated methodology encompassing primary stakeholder interviews, secondary literature analysis, and data triangulation across proprietary and publicly available sources. Expert consultations included neurologists, pharmacoeconomists, payer representatives, and patient advocacy leaders, ensuring balanced perspectives on clinical practice, reimbursement trends, and patient needs.

Secondary research spanned peer-reviewed journals, regulatory filings, and industry databases to validate therapeutic efficacy, safety profiles, and market access pathways. Data were cross-checked through quantitative analysis of prescription volumes, patent landscapes, and tariff schedules, complemented by qualitative assessments of innovation pipelines and partnership dynamics. Rigorous quality assurance protocols, including editorial review and methodological audits, underpin the robustness of our findings and recommendations.

Synthesizing Insights for Future-Focused Action

The Dravet Syndrome landscape is entering an era defined by precision medicine, integrated care models, and stakeholder collaboration. The convergence of innovative drug modalities, adaptive reimbursement strategies, and patient-centric service delivery creates a fertile environment for transformative progress. As tariffs reshape cost structures and regional disparities demand tailored approaches, success will hinge on agility, partnership, and evidence-driven decision-making.

Leaders who embrace segmentation insights, invest in digital ecosystems, and engage proactively with both regulators and patient communities will be best positioned to convert scientific promise into real-world impact. By synthesizing these insights into coherent strategies, stakeholders can accelerate therapeutic breakthroughs, optimize resource allocation, and, most importantly, improve the lives of those affected by this devastating condition.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Cannabinoids
      • Cbd
      • Thc
    • Gaba Modulators
      • Clobazam
      • Diazepam
      • Stiripentol
    • Sodium Channel Blockers
      • Topiramate
      • Valproate
  • End User
    • Home Care
    • Hospital
    • Specialty Epilepsy Centers
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
  • Route Of Administration
    • Injectable
    • Nasal
    • Oral
    • Oromucosal
    • Transdermal
  • Patient Age Group
    • Adolescents
    • Adults
    • Children
    • Infants
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Jazz Pharmaceuticals plc
  • UCB SA
  • Marinus Pharmaceuticals, Inc.
  • Stoke Therapeutics, Inc.
  • Zogenix, Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals, Inc.
  • Xenon Pharmaceuticals Inc.
  • Ovid Therapeutics, Inc.
  • Zynerba Pharmaceuticals, Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dravet Syndrome Market, by Drug Class
8.1. Introduction
8.2. Cannabinoids
8.2.1. Cbd
8.2.2. Thc
8.3. Gaba Modulators
8.3.1. Clobazam
8.3.2. Diazepam
8.3.3. Stiripentol
8.4. Sodium Channel Blockers
8.4.1. Topiramate
8.4.2. Valproate
9. Dravet Syndrome Market, by End User
9.1. Introduction
9.2. Home Care
9.3. Hospital
9.4. Specialty Epilepsy Centers
10. Dravet Syndrome Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.5. Specialty Pharmacies
11. Dravet Syndrome Market, by Route of Administration
11.1. Introduction
11.2. Injectable
11.3. Nasal
11.4. Oral
11.5. Oromucosal
11.6. Transdermal
12. Dravet Syndrome Market, by Patient Age Group
12.1. Introduction
12.2. Adolescents
12.3. Adults
12.4. Children
12.5. Infants
13. Americas Dravet Syndrome Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Dravet Syndrome Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Dravet Syndrome Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Jazz Pharmaceuticals plc
16.3.2. UCB SA
16.3.3. Marinus Pharmaceuticals, Inc.
16.3.4. Stoke Therapeutics, Inc.
16.3.5. Zogenix, Inc.
16.3.6. Biogen Inc.
16.3.7. Ionis Pharmaceuticals, Inc.
16.3.8. Xenon Pharmaceuticals Inc.
16.3.9. Ovid Therapeutics, Inc.
16.3.10. Zynerba Pharmaceuticals, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DRAVET SYNDROME MARKET MULTI-CURRENCY
FIGURE 2. DRAVET SYNDROME MARKET MULTI-LANGUAGE
FIGURE 3. DRAVET SYNDROME MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRAVET SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. CANADA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 60. CANADA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 61. CANADA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 62. CANADA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. CANADA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. CANADA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 66. MEXICO DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 69. MEXICO DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. MEXICO DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. MEXICO DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. GERMANY DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 109. GERMANY DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 110. GERMANY DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 111. GERMANY DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. GERMANY DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. GERMANY DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. GERMANY DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 115. FRANCE DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 117. FRANCE DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 118. FRANCE DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 119. FRANCE DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. FRANCE DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. FRANCE DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. FRANCE DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 131. ITALY DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. ITALY DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 133. ITALY DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 134. ITALY DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 135. ITALY DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. ITALY DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. ITALY DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. ITALY DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 139. SPAIN DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 141. SPAIN DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 142. SPAIN DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 143. SPAIN DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. SPAIN DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. SPAIN DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. SPAIN DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 171. DENMARK DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 173. DENMARK DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 174. DENMARK DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 175. DENMARK DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. DENMARK DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. DENMARK DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. DENMARK DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 187. QATAR DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. QATAR DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 189. QATAR DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 190. QATAR DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 191. QATAR DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. QATAR DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. QATAR DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. QATAR DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. FINLAND DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 197. FINLAND DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 198. FINLAND DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 199. FINLAND DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. FINLAND DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. FINLAND DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. FINLAND DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 219. EGYPT DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 221. EGYPT DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 222. EGYPT DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 223. EGYPT DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. EGYPT DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. EGYPT DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. EGYPT DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 227. TURKEY DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 229. TURKEY DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 230. TURKEY DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 231. TURKEY DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. TURKEY DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. TURKEY DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. TURKEY DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 243. NORWAY DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 245. NORWAY DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 246. NORWAY DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 247. NORWAY DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. NORWAY DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. NORWAY DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. NORWAY DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 251. POLAND DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 252. POLAND DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 253. POLAND DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 254. POLAND DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 255. POLAND DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. POLAND DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. POLAND DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. POLAND DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 276. CHINA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. CHINA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 278. CHINA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 279. CHINA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 280. CHINA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. CHINA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. CHINA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. CHINA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 284. INDIA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 285. INDIA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 286. INDIA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 287. INDIA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 288. INDIA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. INDIA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. INDIA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. INDIA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 292. JAPAN DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 294. JAPAN DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 295. JAPAN DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 296. JAPAN DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. JAPAN DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. JAPAN DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. JAPAN DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 324. THAILAND DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 325. THAILAND DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 326. THAILAND DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 327. THAILAND DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 328. THAILAND DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. THAILAND DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. THAILAND DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 331. THAILAND DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 335. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 336. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 337. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 338. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 339. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 344. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 345. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 346. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 347. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Dravet Syndrome market report include:
  • Jazz Pharmaceuticals plc
  • UCB SA
  • Marinus Pharmaceuticals, Inc.
  • Stoke Therapeutics, Inc.
  • Zogenix, Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals, Inc.
  • Xenon Pharmaceuticals Inc.
  • Ovid Therapeutics, Inc.
  • Zynerba Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 800.08 Million
Forecasted Market Value ( USD ) by 2030 $ 1210 Million
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Dravet Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Dravet Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 77 Pages
  • Global
From
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Global Clinical Trials Review, 2024 - Product Image

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Global Clinical Trials Review, 2024

  • Clinical Trials
  • 134 Pages
  • Global
From
Dravet Syndrome Treatment Market 2025-2029 - Product Image

Dravet Syndrome Treatment Market 2025-2029

  • Report
  • 222 Pages
  • Global
From
Dravet Syndrome- Pipeline Insight, 2025 - Product Image

Dravet Syndrome- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Dravet Syndrome Drug Market

Dravet Syndrome is a rare, severe form of epilepsy that begins in infancy and is characterized by frequent, prolonged seizures. Treatment of Dravet Syndrome typically involves a combination of antiepileptic drugs, dietary therapies, and other therapies. Within the context of Central Nervous System Drugs, the Dravet Syndrome Drug market is a specialized segment of the larger epilepsy drug market. It is composed of drugs that are specifically designed to treat Dravet Syndrome, as well as drugs that are used off-label to treat the condition. The Dravet Syndrome Drug market is composed of both generic and branded drugs. Some of the companies in the market include GW Pharmaceuticals, Zogenix, Eisai, and UCB. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.